FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3040373516> ?p ?o ?g. }

• W3040373516 endingPage "1821" @default.
• W3040373516 startingPage "1808" @default.
• W3040373516 abstract "Low-dose IL-2 (ld-IL2) selectively activates and expands regulatory T cells (Tregs) and thus has the potential to skew the regulatory/effector T (Treg/Teff) cell balance towards improved regulation. We investigated which low doses of IL-2 would more effectively and safely activate Tregs during a 1 year treatment in children with recently diagnosed type 1 diabetes. Dose Finding Study of IL-2 at Ultra-low Dose in Children With Recently Diagnosed Type 1 Diabetes (DF-IL2-Child) was a multicentre, double-blinded, placebo-controlled, dose-finding Phase I/II clinical trial conducted in four centres at university hospitals in France: 24 children (7–14 years old) with type 1 diabetes diagnosed within the previous 3 months were randomly assigned 1:1:1:1 to treatment by a centralised randomisation system, leading to a 7/5/6/6 patient distribution of placebo or IL-2 at doses of 0.125, 0.250 or 0.500 million international units (MIU)/m2, given daily for a 5 day course and then fortnightly for 1 year. A study number was attributed to patients by an investigator unaware of the randomisation list and all participants as well as investigators and staff involved in the study conduct and analyses were blinded to treatments. The primary outcome was change in Tregs, expressed as a percentage of CD4+ T cells at day 5. It pre-specified that a ≥60% increase in Tregs from baseline would identify Treg high responders. There were no serious adverse events. Non-serious adverse events (NSAEs) were transient and mild to moderate. In treated patients vs placebo, the commonest NSAE was injection site reaction (37.9% vs 3.4%), whereas other NSAEs were at the same level (23.3% vs 19.2%). ld-IL2 induced a dose-dependent increase in the mean proportion of Tregs, from 23.9% (95% CI −11.8, 59.6) at the lowest to 77.2% (44.7, 109.8) at the highest dose, which was significantly different from placebo for all dose groups. However, the individual Treg responses to IL-2 were variable and fluctuated over time. Seven patients, all among those treated with the 0.250 and 0.500 MIU m−2 day−1 doses, were Treg high responders. At baseline, they had lower Treg proportions in CD4+ cells than Treg low responders, and serum soluble IL-2 receptor α (sIL-2RA) and vascular endothelial growth factor receptor 2 (VEGFR2) levels predicted the Treg response after the 5 day course. There was no significant change in glycaemic control in any of the dose groups compared with placebo. However, there was an improved maintenance of induced C-peptide production at 1 year in the seven Treg high responders as compared with low responders. The safety profile at all doses, the dose-dependent effects on Tregs and the observed variability of the Treg response to ld-IL2 in children with newly diagnosed type 1 diabetes call for use of the highest dose in future developments. The better preservation of insulin production in Treg high responders supports the potential of Tregs in regulating autoimmunity in type 1 diabetes, and warrants pursuing the investigation of ld-IL2 for its treatment and prevention. ClinicalTrials.gov NCT01862120. Assistance Publique-Hôpitaux de Paris, Investissements d’Avenir programme (ANR-11-IDEX-0004-02, LabEx Transimmunom and ANR-16-RHUS-0001, RHU iMAP) and European Research Council Advanced Grant (FP7-IDEAS-ERC-322856, TRiPoD)." @default.
• W3040373516 created "2020-07-10" @default.
• W3040373516 creator A5002318440 @default.
• W3040373516 creator A5003561098 @default.
• W3040373516 creator A5008463844 @default.
• W3040373516 creator A5021691892 @default.
• W3040373516 creator A5025877737 @default.
• W3040373516 creator A5025957192 @default.
• W3040373516 creator A5027712968 @default.
• W3040373516 creator A5040930956 @default.
• W3040373516 creator A5041012767 @default.
• W3040373516 creator A5044456322 @default.
• W3040373516 creator A5045688488 @default.
• W3040373516 creator A5050887342 @default.
• W3040373516 creator A5062194432 @default.
• W3040373516 creator A5075249362 @default.
• W3040373516 creator A5077054564 @default.
• W3040373516 creator A5082718407 @default.
• W3040373516 creator A5087729976 @default.
• W3040373516 creator A5088096181 @default.
• W3040373516 date "2020-07-01" @default.
• W3040373516 modified "2023-10-17" @default.
• W3040373516 title "Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study" @default.
• W3040373516 cites W1869108512 @default.
• W3040373516 cites W1970246068 @default.
• W3040373516 cites W1986742496 @default.
• W3040373516 cites W2014003029 @default.
• W3040373516 cites W2032218738 @default.
• W3040373516 cites W2074214836 @default.
• W3040373516 cites W2085106134 @default.
• W3040373516 cites W2086595653 @default.
• W3040373516 cites W2086814528 @default.
• W3040373516 cites W2099862791 @default.
• W3040373516 cites W2102201073 @default.
• W3040373516 cites W2106107076 @default.
• W3040373516 cites W2115135853 @default.
• W3040373516 cites W2120813964 @default.
• W3040373516 cites W2130778427 @default.
• W3040373516 cites W2132051812 @default.
• W3040373516 cites W2135280067 @default.
• W3040373516 cites W2138949572 @default.
• W3040373516 cites W2144147645 @default.
• W3040373516 cites W2147557220 @default.
• W3040373516 cites W2148360092 @default.
• W3040373516 cites W2150631622 @default.
• W3040373516 cites W2162675860 @default.
• W3040373516 cites W2163665000 @default.
• W3040373516 cites W2169258115 @default.
• W3040373516 cites W2169820627 @default.
• W3040373516 cites W2222964685 @default.
• W3040373516 cites W2315874408 @default.
• W3040373516 cites W2531773523 @default.
• W3040373516 cites W2606106417 @default.
• W3040373516 cites W2752229394 @default.
• W3040373516 cites W2800686997 @default.
• W3040373516 cites W2895525787 @default.
• W3040373516 cites W2896517179 @default.
• W3040373516 cites W2901041673 @default.
• W3040373516 cites W2948104235 @default.
• W3040373516 cites W2968822740 @default.
• W3040373516 cites W2976856562 @default.
• W3040373516 cites W2997332520 @default.
• W3040373516 cites W3008321272 @default.
• W3040373516 cites W4244908740 @default.
• W3040373516 cites W4250286899 @default.
• W3040373516 cites W4375932018 @default.
• W3040373516 doi "https://doi.org/10.1007/s00125-020-05200-w" @default.
• W3040373516 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32607749" @default.
• W3040373516 hasPublicationYear "2020" @default.
• W3040373516 type Work @default.
• W3040373516 sameAs 3040373516 @default.
• W3040373516 citedByCount "38" @default.
• W3040373516 countsByYear W30403735162020 @default.
• W3040373516 countsByYear W30403735162021 @default.
• W3040373516 countsByYear W30403735162022 @default.
• W3040373516 countsByYear W30403735162023 @default.
• W3040373516 crossrefType "journal-article" @default.
• W3040373516 hasAuthorship W3040373516A5002318440 @default.
• W3040373516 hasAuthorship W3040373516A5003561098 @default.
• W3040373516 hasAuthorship W3040373516A5008463844 @default.
• W3040373516 hasAuthorship W3040373516A5021691892 @default.
• W3040373516 hasAuthorship W3040373516A5025877737 @default.
• W3040373516 hasAuthorship W3040373516A5025957192 @default.
• W3040373516 hasAuthorship W3040373516A5027712968 @default.
• W3040373516 hasAuthorship W3040373516A5040930956 @default.
• W3040373516 hasAuthorship W3040373516A5041012767 @default.
• W3040373516 hasAuthorship W3040373516A5044456322 @default.
• W3040373516 hasAuthorship W3040373516A5045688488 @default.
• W3040373516 hasAuthorship W3040373516A5050887342 @default.
• W3040373516 hasAuthorship W3040373516A5062194432 @default.
• W3040373516 hasAuthorship W3040373516A5075249362 @default.
• W3040373516 hasAuthorship W3040373516A5077054564 @default.
• W3040373516 hasAuthorship W3040373516A5082718407 @default.
• W3040373516 hasAuthorship W3040373516A5087729976 @default.
• W3040373516 hasAuthorship W3040373516A5088096181 @default.
• W3040373516 hasBestOaLocation W30403735161 @default.
• W3040373516 hasConcept C126322002 @default.
• W3040373516 hasConcept C134018914 @default.

• next